

Graviola: A Systematic Review on Its Anticancer Properties

Patrikios Ioannis*, Stephanou Anastasis, Yiallouris Andreas

School of Medicine, European University Cyprus, Nicosia, Cyprus

*Corresponding author: i.patrikios@euc.ac.cy

Abstract There has been an enormous interest in the literature that phyto-compounds have therapeutic and beneficial effects in various diseases including inflammatory associated arthritis, diabetes, hypertension, parasitic infections, and cancer. The leaves from the tropical tree *Annona Muricata*, also known as Graviola have been reported to have positive and effective properties against many of the above mentioned diseases. Cancer still remains the number one killer in the Western nations and most treatments for the disease rely on the use of chemotherapy that utilizes drugs that are also toxic against normal healthy cells. Thus, an alternative approach to anti-cancer therapies should involve the determination of novel drug targets that must be highly effective and specific against cancer development and growth. Additionally, the new generation novel drugs should be non-toxic to the host cells and affordable for the patients. This review summarizes the recent findings on the effects of Graviola tree extract as a novel anti-cancer agent for the treatment and prevention of cancers; a possible natural anti-cancer candidate agent in line with all the attributes pointed above.

Keywords: cell death, apoptosis, necrosis, Graviola, anti-cancer agents, cancer, tumor

Cite This Article: Patrikios Ioannis, Stephanou Anastasis, and Yiallouris Andreas, "Graviola: A Systematic Review on Its Anticancer Properties." *American Journal of Cancer Prevention*, vol. 3, no. 6 (2015): 128-131. doi: 10.12691/ajcp-3-6-5.

1. Natural Extracts against Cancer

Natural Plant extracts have been used for centuries by many cultures and civilizations as a basis for treating various diseases. More than 80% of the global population now depends on natural plant extracts through traditional therapies. [1,2,3] Recent investigators have focused on the progression, treatment and prevention of cancer with such compounds but room for improvement still remains.

To date, the use of conventional synthetic chemotherapeutic drugs lack the properties to be considered as effective therapeutic agents, with most of those associated with severe side effects and toxicity of the normal host cells. Whereas an alternative therapeutic approach that uses natural plant extracts is advantageous vs conventional therapy with limited side effects.

One of the first systematic approaches was carried out in 1950 with the vinca alkaloids (vinblastin and vincristine) discovery, isolated from the *Catharanthus roseus* G. Don. (Apocynaceae) followed by a number of effective extracts such as Triptolide (*Tripterigium wilfordii*), Amygdalin (B12), *Achyranthes aspera* Linn. (Family-Amaranthaceae) etc [4,5,6].

2. Graviola History

Graviola belongs to *Annonaceae* family, *Annona* genus and *muricata* species. Graviola is a fruit tree with many uses in traditional and alternative medicine. Graviola,

soursop, guanábana, guanábano, guanavana, guanaba, corossol épineux, huanaba, toge-banreisi, durian benggala, nangka blanda, cachiman épineux are altering names for this evergreen plant that is mostly distributed in tropical and subtropical regions of the world. Graviola is a heart shaped edible fruit and together with its leaves, root and seeds is known to have beneficial properties in alternative medicine [7].

The fruits of Graviola are extensively used to make candies, syrups, ice creams, shakes and beverages. A wide range of ethno-medicinal activities in Africa and South America extensively use this plant in their conventional medicine. A number of laboratories have reported Graviola's for its beneficial actions against anticonvulsant, antiparasitic, anti-arthritic, antimalarial, antidiabetic hepatoprotective and anticancer activities. Biological and chemical characterization studies indicate that annonaceous acetogenins are the main ingredients of Graviola [8,9,10].

Nowadays more than 100 annonaceous acetogenins that are generally characterized as a family of natural products with antitumor activities, from roots, leaves, barks, fruits and seeds of Graviola have been widely used in alternative medicine for many purposes. In the Peruvian Andes for example, the Graviola leaves are used to combat parasites and treat diabetes. In the Brazilian Amazon the leaves were used to treat liver problems and the leave – extracted oil is believed to help with rheumatism, neuralgia and arthritis. In the Eastern Andes and Jamaica, Haiti the juice of Graviola was used to stop diarrhea, used as muscle relaxant and lower the intestinal acidity [11-15].

Other reports have demonstrated that Graviola has a number of biological activities such as antifungal, anti-bacterial, anti-malarial and antioxidant. Furthermore, it has been showed to have anti-cancer properties on multi-drug resistant cancer cell lines. [16,17,18,19,20] The ability of Graviola to have selective growth inhibition against a variety of cancer cells including lung carcinoma cell lines, breast solid tumor lines, prostate adenocarcinoma, pancreatic carcinoma cell lines, colon adenocarcinoma cell lines, liver cancer cell lines, human lymphoma cell lines, and multi-drug resistant human breast adenocarcinoma will be discussed based on previously published data [21,22,23,24,25,26].

2.1. Composition

Graviolas fruit flesh consists of 80% water, 1% protein, 18% carbohydrates and small amount of vitamins B, B2, C, potassium and dietary fiber. [27,28] The main group, annonaceous acetogenin, is a unique set of derivatives of C35 or C37 long chain fatty acids derived from the polyketide pathway (Figure 1). The annonaceous acetogenins found in Graviola include Annocatalin, annohexocin, annomonicin, annomontacin, annomuricin A & B, annomuricin A thru E, annomutacin, annonacin, annonacinone, annopentocin A thru C, cis-annonacin, cis-corosolone, cohibin A thru D, coreoxylone, coronin, corosolin, corosolone, donhexocin, epomuricin A & B, gigantetrocin, gigantetrocin A & B, gigantetrocinone, gigantetronenin, goniothalamycin, iso-annonacin, javoricin, montanacin, montecristin, muracin A thru G, muricapentocin, muricatalin, muricatalin, muri-catenol, uricatetrocin A & B muricatin D, muricatocin A thru C muricin H, muricin I, muricoreacin, murihexocin 3, murihexocin A thru C, murihexol, murisolin, robustocin, rolliniastatin 1 & 2, saba-delin, solamin, uvariamicin I & IV, xylomaticin isolated from the leaves, root and stem barks of Graviola [29,30,31].




Figure 1. Bullatacin chemical structure, one out of the three main annonaceous acetogenin molecules including asimicin and bullatalicin that it is believed to be the one most bio-active anti-cancer molecule found in the Graviola extract

The essential oil of the fresh fruit pulp contains 2-hexenoic acid methyl ester (23.9%), 2-hexenoic acid ethyl ester (8.6%), 2-octenoic acid methyl ester (5.4%), 2-butenic acid methyl ester (2.4%), β -caryophyllene (12.7%), 1,8-cineole (9.9%), linalool (7.8%), α -terpineol (2.8%), lialyl propionate (2.2%) and calarence (2.2%) [32].

Limited number of published data are found in literature for the anti-carcinogenic potential of Graviola natural extracts. Recent studies have suggested that

Graviola also expresses analgesic and anti-inflammatory effects, promotes apoptosis (programmed cell death) and cytotoxicity on cancer cells that may result from the presence of alkaloids, essential oils and acetogenins. [11,33,34,35] These acetogenins demonstrated to be selective and toxic against various types of cancer cells without harming normal and healthy host cells [36,37,38].

2.2. Anticancer Characteristics

It has been previously reported that the Graviola extracts have significant anti-cancer effects in a number of cancer cell lines both *in vitro* and *in vivo*. [39] Studies revealed the Graviola extracts as having selective inhibition of breast cancer cells via EGFR downregulation. The epidermal growth factor receptor (EGFR) is an oncogene frequently overexpressed in breast cancer (BC), and its overexpression has been associated with poor prognosis and drug resistance. EGFR is therefore a rational target for BC therapy development. In addition, experiments showed that Graviola fruit extract (GFE) inhibit the growth of BC cells using xenografts mouse model studies. Moreover, GFE selectively inhibited the growth of EGFR-overexpressing human BC (MDA-MB-468) cells but not in non-tumorigenic human breast epithelial cells (MCF-10A). [39] These studies strengthen the evidence that Graviola has selective anti-growth effects between cancer and non-cancer cells.

Another study on breast cancer cells supported that Graviola promotes apoptosis in ER-related pathways. Moreover, Graviola decreased MCF-7 tumor growth while inhibiting ER-cyclin D1 and Bcl-2 protein expressions in nude mice. [40] In colon cancer cells, Graviola leaves also has significant effects on cell survival potential via mitochondrial-mediated apoptosis associated with the G1 cell cycle arrest. Graviola induces apoptosis by generating reactive oxygen species ROS and down-regulating the anti-apoptotic Bcl-2 protein, while up-regulating pro-apoptotic Bax protein. These processes subsequently lead to attenuation of mitochondrial membrane potential (MMP) and cytochrome c release. Release of cytochrome c activates apoptosome and the intrinsic caspase cascade that triggers execution of apoptosis through DNA fragmentation. [41] Graviola has also been reported to have anti-proliferative effects of HL-60 cells via loss of cell viability, loss of MMP, G0/G1 phase cell arrest and morphological apoptotic changes. These results substantiate and confirm that Graviola does indeed have anti-proliferative and cytostatic activity in HL-60 cells [42].

In Vitro and *in vivo* model studies demonstrated the effect of Graviola extract in prostate cancer cell lines. These experiments showed that Graviola promotes necrosis in PC-3 cells through inhibition of tumor mobility and cellular metabolism. Further studies demonstrated downregulation of the expression of the hypoxia-related factors and glycolytic factors following treatment in PC cells with Graviola (i.e. HIF-1 α , NF- κ B, GLUT1, GLUT4, HKII, and LDHA) [26].

Follow up studies reported the *in vivo* Graviola leaf extract (GLE) pharmacokinetics and *in vitro* absorption kinetics resulting in inhibiting *in vitro* prostate cancer proliferation, viability and clonogenic colonies. Oral administration of 100mg/kg bw GLE showed tumor growth-inhibition in human prostate tumor in xenografts

studies. This study also demonstrated the synergy among the constituents of Graviola leaf extract (GLE) compared to its flavonoid-enriched (FEF) and acetogenin-enriched (AEF) fractions [43,54].

In another study Graviola also had effects on Lewis lung carcinoma (LLC) tumor cell lines that were examined both *in vivo* as well as *in vitro*. The study suggested that Graviola once again had antitumor activity by inhibiting the normal growth of the lung tumors. [47] Further studies also indicated the anti-cancerous and cytotoxic mechanisms of action of Graviola that affected NADH oxidase inhibition in cancer cell lines, downregulation of the P-glycoprotein pump via ATP depletion and Cell cycle arrest at S-phase progression [48,49,50,51].

A recently published study demonstrated also the preventive measure against 7,12-dimethylbenzanthracene DMBA-induced breast cell proliferation in the breast tissues of female albino mice. Once again, the study supported that the Graviola leaf extract could act as a cancer prevention agent [52].

3. Concluding Remarks

Overall, this mini review lists the existing knowledge about the natural plant extract agent, Graviola, and gives an insight on the important *in vitro* and *in vivo* studies that

have been carried out based on its efficacy and functional characteristics. However, further studies are required to verify the exact properties and the mechanisms of action. Even though several reports demonstrated positive actions of Graviola, more robust and systematic clinical trials to test and verify its true validity and safety are necessary, in order to be confirmed as a therapeutic anti-cancer agent. Thus, well-designed, randomized, double blind trials are of major importance.

Concluding, the present review demonstrates the advantages of the possible use of Graviola for cancer treatment. Existing conventional cancer therapies are known to be highly toxic with severe side-effects that affect the quality of life of the patients and with no more than 6 months contribution of life expectancy [56,57]. Therefore, new drugs need to be developed that include bioactive natural molecules such as Graviola that do not have toxic side-effects and are selective in killing cancer cells but not the normal/physiological healthy host cells. Furthermore, pro-inflammatory responses and pathways are activated and suggested to play an important, primary role in tumourgenesis. Graviola with known strong anti-inflammatory effects can warrant a new *in vivo* study to determine whether one mechanism of action, could possibly be, through specifically inhibiting the site of inflammation in solid cancers [53,55].

Table 1. Scientific findings of previously published work on Graviola.

| Trial type | Findings | Randomized | References |
|-----------------|---|------------|---|
| <i>In Vivo</i> | Graviola decreased MCF-7 tumor growth in nude mice. | No | Yu-Min Koa et al.(2011) [40] |
| <i>In Vivo</i> | Graviola has antitumor activity in lung cancer cells. | No | Wang, L. Q., et al (2002) [44] Woo, M. H., et al (1999) [45] |
| <i>In Vivo</i> | Graviola could act as a cancer prevention agent. | No | J.B. Minari *, U. Okeke (2014) [52] |
| <i>In vitro</i> | Graviola selectively inhibited the growth of EGFR-overexpressing human breast cancer cells. | *N/A | Dai Y, Hogan Set al. (2011) [39] |
| <i>In vitro</i> | Graviola induces apoptosis in colon cancer cells. | N/A | Soheil Zorofchian Moghadamtousi et al.(2014) [41] |
| <i>In vitro</i> | Graviola promotes necrosis in PC-3 cells. | N/A | Torres, M. P et al. (2012) [26] Yang C et al. (2015) [43] |
| <i>In vitro</i> | Graviola has antitumor activity in Lung cancer. | N/A | Kim, G. S., et al. (1998) [46] Zhao, G. X., et al. (1993) [47] |

*N/A Not Applicable.

References

- [1] Ignacimuthu S, Ayyanar M, Sivaraman S.K., Ethnobotanical investigations among tribes in Madurai district of Tamil Nadu (India). *Journal of Ethnobiology and Ethnomedicine*, 2. 1. 2006.
- [2] Elujoba A. A., Odeleye O. M., Ogunyemi C. M., Traditional medicine development for medical and dental primary health care delivery system in Africa. *African Journal of Traditional, Complementary and Alternative Medicines*, 2. 46. 2005.
- [3] Tomlinson T. R., Akerele O. Medicinal plants: their role in health and biodiversity. University of Pennsylvania Press, Philadelphia, 1998.
- [4] Gordon M. C., David J., Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology*, 100. 72. 2005.
- [5] Gueritte F., Fahy J., The vinca alkaloids. In *Anticancer Agents from Natural Products*, edited by Cragg GM, Kingston DGI, Newman DJ. Brunner-Routledge Psychology Press, Taylor & Francis Group, Boca Raton, Chapter 7. 23. 2005.
- [6] Patrikios Ioannis, Stephanou Anastasis, Yiallouris Andreas. Tripterygium Wilfordii Extract (Triptolide) and Amygdalin Promotes Cell death in Cancer Cells: True or a Myth. *American Journal of Cancer Prevention* Vol. 3, No. 4, 2015, pp 77-83.
- [7] Mishra, S.; Ahmad, S.; Kumar, N.; Sharma, B.K. *Annona muricata*(the cancer killer): A review. *Glob. J. Pharm. Res.* 2013, 2, 1613-1618.
- [8] Leboeuf, M.; Cavé, A.; Bhaumik, P.; Mukherjee, B.; Mukherjee, R. The phytochemistry of the annonaceae. *Phytochemistry*1980, 21, 2783-2813.
- [9] Adewole, S.O.; Caxton-Martins, E.A. Morphological changes and hypoglycemic effects of *Annona muricata*Linn. (Annonaceae) leaf aqueous extract on pancreatic B-cells of streptozotocin-treated diabetic rats. *Afr. J. Biomed. Res.* 2006, 9, 173-187.
- [10] De Souza, R.; Benassi, E.; da Silva, R.R.; Afonso, S.; Scarminio, I.S. Enhanced extraction yields and mobile phase separations by solvent mixtures for the analysis of metabolites in *Annona muricata* L. Leaves. *J. Sep. Sci.* 2009, 32, 4176-4185.
- [11] De Sousa, O.V.; Vieira, G.D.-V.; de Pinho, J.D.J.R.; Yamamoto, C.H.; Alves, M.S. Antinociceptive and anti-inflammatory activities of the ethanol extract of *Annona muricata*L.leaves in animal models. *Int. J. Mol. Sci.* 2010, 11, 2067-2078.
- [12] Adewole, S.; Ojewole, J. Protective effects of *Annona muricata*linn.(annonaceae) leaf aqueous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic rats. *Afr. J. Tradit. Complement. Altern. Med.* 2009, 6, 30-41.
- [13] Watt, J.M.; Breyer-Bnodwijk, M. *The Medicinal and Poisonous Plants of Southern and Eastern Africa: Being an Account of Their Medicinal and Other Uses, Chemical Composition, Pharmacological Effects and Toxicology in Man and Animal*; Livingston Ltd.: Edinburgh, UK; London, UK, 1962.
- [14] Jaramillo-Flores, M.; Hernandez-Sanchez, H. Thermal diffusivity of soursop (*Annona muricata* L.) pulp. *J. Food Eng.* 2000, 46, 139-143.
- [15] Wu, F.-E.; Gu, Z.-M.; Zeng, L.; Zhao, G.-X.; Zhang, Y.; McLaughlin, J.L. Sastrodihardjo, S. Two new cytotoxic monotetrahydrofuran annonaceous acetogenins, annomuricinsa and b, from the leaves of *Annona muricata*. *J. Nat. Prod.* 1995, 58, 830-836.

- [16] Vieira GHF, Mourão JA, Ângelo ÂM, Costa RA, Vieira SDF: Antibacterial effect (in vitro) of *Moringaoleifera* and *Annona muricata* against gram positive and gram negative bacteria. *Rev Inst Med Trop Sao Paulo* 2010, 52(3):129-132.
- [17] Heinrich M, Kuhnt M, Wright CW, Rimpler H, Phillipson JD, Schandelmaier A, Warhurst DC: Parasitological and microbiological evaluation of mixe Indian medicinal plants (Mexico). *J Ethnopharmacol* 1992, 36:81-85.
- [18] Antoun MD, Gerena L, Milhus WK: Screening of the flora of Puerto rico for potential antimalarial bioactives. *Int J Pharmacol* 1993, 31:255-258.
- [19] Baskar R, Rajeswari V, Kumar TS: In vitro antioxidant studies in leaves of *annona* species. *Indian J ExpBiol* 2007, 4:480-485.
- [20] Luna Jde S, De Carvalho JM, De Lima MR, Bieber LW, Bento Ede S, Franck X, Sant'ana AE: Acetogenins in *Annona muricata* L. (annonaceae) leaves are potent molluscicides. *Nat Prod Res* 2006, 20:253-257.
- [21] Rieser, M. J.; Gu, Z. M.; Fang, X. P.; Zeng, L.; Wood, K. V.; McLaughlin, J. L. Five novel mono-tetrahydrofuran ring acetogenins from the seeds of *Annona muricata*. *J Nat. Prod.* 1996, 59, 100.
- [22] Kim, G. S.; Zeng, L.; Alali, F.; Rogers, L. L.; Wu, F. E.; Sastrodihardjo, S.; McLaughlin, Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of *Annona muricata*. *J. Phytochem.* 1998, 49, 565.
- [23] Chang, F. R.; Wu, Y. C. Novel cytotoxic annonaceous acetogenins from *Annona muricata*. *J Nat. Prod.* 2001, 64, 925.
- [24] Liaw, C. C.; Chang, F. R.; Lin, C. Y.; Chou, C. J.; Chiu, H. F.; Wu, M. J.; Wu, Y. C. J New cytotoxic monotetrahydrofuran annonaceous acetogenins from *Annona muricata*. *Nat. Prod.* 2002, 65, 470.
- [25] Chang, F. R.; Liaw, C. C.; Lin, C. Y.; Chou, C. J.; Chiu, H. F.; Wu, Y. C. New adjacent Bis-tetrahydrofuran Annonaceous acetogenins from *Annona muricata*. *Planta Medica* 2003, 69, 241.
- [26] Torres, M. P.; Rachagani, S.; Purohit, V.; Pandey, P.; Joshi, S.; Moore, E. D.; Johansson, S. L.; Singh, P. K.; Ganti, A. K.; Batra, S. K. *Graviola*: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. *Cancer Lett.* 2012, 323, 29.
- [27] Hann J: A history of the Tumucua Indians and mission. Florida: University Press; 1996:13-21.
- [28] Pier O: Pacific island ecosystem at risk, "Result set for: Annonaceae *Annona muricata*". United States Geological Survey and United States Forest Service: Pier species lists; 2008:8.
- [29] Rieser MJ, Kozlowski JF, Wood KV, McLaughlin J: Muricatacin: a simple biologically active acetogenin derivative from the seeds of *Annona muricata* (Annonaceae). *Tetrahedron Lett* 1991, 32:1137-1140.
- [30] CosmeKossouh , Mansour Moudachirou , Victor Adjakidje , Jean-Claude Chalchat c& Gilles Figuéredo. Essential Oil Chemical Composition of *Annona muricata* L. Leaves from Benin, *Journal of Essential Oil Research*(2007),19:4, 307-309,
- [31] Badrie N. and Schauss A.G. Soursop (*Annona muricata* L.): Composition, Nutritional Value, Medicinal Uses, and Toxicology, *Bioactive Foods in Promoting Health*, 2010, Ch. 39: 621-641
- [32] Sulaiman H, Roslida AH, Fezah O, Tan KL, Tor YS, Tan CI: Chemopreventive potential of *Annona Muricata* L Leaves on chemically-Induced skin papillomagenesis in mice. *Asian Pac J Cancer Prev* 2012, 13:2532-2533.
- [33] Leboeuf M, Cavé A, Bhaumik PK, Mukherjee B, Mukherjee R: The phytochemistry of the annonaceae. *Phytochem* 1982, 21:2783-2813.
- [34] Kossouh C, Moudachirou M, Adjakidje V, Chalchat JC, Figuéredo G: Essential oil chemical composition of *Annona muricata* L. leaves from Benin. *J Ess Oil Res* 2007, 19:307-309.
- [35] Chang FR, Liaw CC, Lin CY, Chou CJ, Chiu HF, Wu YC: New adjacent bis-tetrahydrofuran annonaceous acetogenins from *Annona muricata*. *Planta Med* 2003, 69:241-246.
- [36] Ekaprasasti NR, Tuti SS, Retno WA: The breast of anticancer from leaf extract of *Annona muricata* againsts cell line in t47d. *Int J Applied Sci Technol* 2012, 2(1):157-164.
- [37] Gajalakshmi S, Vijayalakshmi S, Devi. Rajeswari V: Phytochemical and pharmacological properties of *Annona muricata*: a review. *Int J Pharm PharmSci* 2012, 4(2):3-6.
- [38] Ragasa CY, Soriano G, Torres OB, Don MJ, Shen CC: Acetogenins from *Annona muricata*. *Phcog J* 2012, 32(4):32-37.
- [39] Dai Y, Hogan S, Schmelz EM, Ju YH, Canning C, Zhou K. Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. *Nutr Cancer.* 2011; 63:795-801. [PubMed: 21767082].
- [40] Yu-Min Koa, Tung-Ying Wub, Yang-Chang Wub, Fang-Rong Changb, Jinn-Yuh Guhc,d,*, Lea-Yea Chuange,* Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor--related pathways in MCF-7 cells. *Journal of Ethnopharmacology.* 137 (2011) 1283-1290.
- [41] Soheil Zorofchian Moghadamtousi, Hamed Karimian, Elham Rouhollahi, Mohammadjavad Paydar, Mehran Fadaeinasab, Habsah Abdul Kadir. *Annona muricata* leaves induce G1 cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells *Journal of Ethnopharmacology* 156 (2014) 277-289.
- [42] Constant Anatole Pieme, Santosh Guru Kumar, Mireille Sylviane Dongmo, Bruno Moukette Moukette1, Fabrice Fekam Boyoum4, Jeanne Yonkeu Ngogang and Ajit Kumar Saxena. Antiproliferative activity and induction of apoptosis by *Annona muricata* (Annonaceae) bextract on human cancer cells. Pieme et al. *BMC Complementary and Alternative Medicine* 2014, 14:516.
- [43] Yang C¹, Gundala SR¹, Mukkavilli R², Vangala S³, Reid MD⁴, Aneja R⁵. Synergistic interactions among flavonoids and acetogenins in *Graviola* (*Annona muricata*) leaves confer protection against prostate cancer. *Carcinogenesis.* 2015 Jun;36(6):656-65. doi: 10.1093/carcin/bgv046. Epub 2015 Apr 11.
- [44] Wang, L. Q., Min BS, Li Y, Nakamura N, Qin GW, Li CJ, Hattori M. "Annonaceous acetogenins from the leaves of *Annona montana*." *Bioorg. Med. Chem.* 2002;10(3):561-5.
- [45] Woo, M. H., Chung, S. O. & Kim, D. H. "Cis-annonacin and (2,4)-cis- and trans-isoannonacins: cytotoxic monotetrahydrofuran annonaceous acetogenins from the seeds of *Annona cherimolia*." *Arch. Pharm. Res.* 1999; 22(5): 524-8.
- [46] Kim GS, Zeng L, Alali F, Rogers LL, Wu FE. "Muricoreacin and murihexocin c, mono-tetrahydrofuran acetogenins, from the leaves of *Annona muricata*." *Phytochemistry* 1998; 49(2): 565-571.
- [47] Zhao GX1, Rieser MJ, Hui YH, Miesbauer LR, Smith DL, McLaughlin JL. "Biologically active acetogenins from stem bark of *Asiminatriliba*." *Phytochemistry* 1993; 33(5): 1065-73.
- [48] Alali FQ1, Liu XX, McLaughlin JL. "Annonaceous acetogenins: Recent progress." *J. Nat. Prod.* 1999; 62(3): 504-540.
- [49] Morre DJ, de Cabo R, Farley C, Oberlies NH, McLaughlin JL. "Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH oxidase activity of HeLa and HL-60, but not liver, plasma membranes." *Life Sci.* 1995; 56(5): 343-8.
- [50] Nicholas H. Oberlies, Ching-je Chang, and Jerry L. McLaughlin. "Structure-activity relationships of diverse annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells." *J. Med. Chem.* 1997; 40(13): 2101-2106
- [51] González-Coloma A1, Guadaño A, de Inés C, Martínez-Díaz R, Cortes D. "Selective action of acetogenin mitochondrial complex I inhibitors." *Z. Naturforsch* 2002; 57(11-12): 1028-34.
- [52] J.B. Minari *, U. Okeke. Chemopreventive effect of *Annona muricata* on DMBA-induced cell proliferation in the breast tissues of female albino mice. *The Egyptian Journal of Medical Human Genetics* (2014) 15, 327-334.
- [53] Fernandes JV1, Cobucci RN, Jatobá CA, Fernandes TA, de Azevedo JW, de Araújo JM. The role of the mediators of inflammation in cancer development. *Pathol Oncol Res.* 2015 Jul;21(3):527-34.
- [54] Jenö Paul, R. Gnanam, R. M. Jayadeepa and L. Arul. Anti-Cancer Activity on *Graviola*, Exciting Medicinal Plant Extract vs Various Cancer Cell Lines and a Detailed Computational Study on its Potent Anti-Cancerous Leads. *Current Topics in Medicinal Chemistry* 2013. V.13:1666-1673:8.
- [55] Jayashree BS, Nigam S, Pai A, Patel HK, Reddy ND, Kumar N, Rao CM. Targets in anticancer research--A review. *Indian J Exp Biol.* 2015 Aug; 53(8):489-507.
- [56] C.W. Taylor, A.M. Kirby. Cardiac Side-effects From Breast Cancer Radiotherapy. *Clinical Oncology* 27 (2015) 621-629.
- [57] Christina H. Ruhlmann, Trine Zeeberg Iversen, Meena Okera, Aida Muhic, Gunnar Kristensen Petra Feyer, Olfred Hansen. Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy *Radiother. Oncol.* 2015.09.014.